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Objective: To dissect the correlated hematologic markers that reﬂect the clinical outcome or treatment
response in patients receiving dose-dense chemotherapy with a combination of platinum (cisplatin or
carboplatin) and paclitaxel.
Materials and Methods: From 2009 to 2014, we enrolled 55 ovarian cancer patients (total 67 courses)
including ﬁrst-line, persistent, platinum-sensitive, or platinum-resistant disease in MacKay Memorial
Hospital, Taipei, Taiwan. Weekly pretreatment complete blood counts and calculated ratios [platelet/
neutrophil ratio, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), neutrophil/mono-
cyte ratio, platelet/monocyte ratio, lymphocyte/monocyte ratio] during dose-dense chemotherapy were
collected. By grouping these hematologic biomarkers into three different response subgroups (respon-
sive, stable, and nonresponsive) according to CA125 trend, the data were analyzed using one-way
analysis of variance, and using post hoc-Tukey test for comparing each other. A p value < 0.05 was
considered to be statistically signiﬁcant.
Results: Absolute counts of lymphocytes and platelets, PLR, platelet/neutrophil ratio, platelet/monocyte
ratio (all p < 0.001), and NLR (p¼ 0.013) had statistically signiﬁcant differences. Moreover, using box-
and-whisker plot, absolute count of lymphocyte, PLR, and NLR showed most remarkable discrepancy
in responsive, stable, and nonresponsive patients. Subgroup analysis for primary, platinum-sensitive, and
platinum-resistant patients further revealed that PLR and NLR were signiﬁcantly correlated to the
outcome of dose-dense chemotherapy.
Conclusion: Lower PLR or lower NLR had better treatment response for dose-dense chemotherapy and
are possible markers for representing treatment response in dose-dense chemotherapy. For a clinician,
this is useful for timing when to switch to another chemotherapy regimen.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Epithelial ovarian cancer is the ﬁfth leading cause of cancer-
related death among women. Evidence has established tumor
debulking surgery followed by a platinum-based chemotherapy as
the ﬁrst-line therapy for advanced ovarian cancer, yielding
response rates of > 80%. However, for platinum-resistant ovarian
cancer, second-line cytotoxic agents only achieve a 15e20%s and Gynecology, Mackay
Road, Taipei, Taiwan.
).
bstetrics & Gynecology. Published bresponse rate. Nowadays studies are still seeking another possible
mode, schedule, or regimen of chemotherapeutic strategies.
Chemotherapy reﬁnement and optimization might be the other
focus to overcome the development of drug resistance and
improve the survival of the patients. The standard regimen of
chemotherapy for advanced ovarian cancer is combination of
platinum (cisplatin or carboplatin) and paclitaxel and response
rates have been reported in 73% of those receiving cisplatin/
paclitaxel and in 60% of those receiving cisplatin/cyclophospha-
mide combinations [1].
The concept of dose-dense therapy was deﬁned by the Nor-
toneSimon regression hypothesis, which was proposed in the




Course number 67 (1e3 courses)
First 11 (16%)
Persistent disease 4 (6%)
Platinum-sensitive 26 (39%)
Platinum-resistant 26 (39%)
Age (y) 54.8 (33e81)
Treatment duration 194.6 (45e1122)
Figure 1. Schedule for dose-dense chemotherapy. The patients had pretreatment pe-
ripheral blood tests on the mornings of Day 1, Day 8, and Day 15. If the result of blood
test was acceptable, dose-dense chemotherapy with paclitaxel (60e80 mg/m2) plus
platinum [carboplatin (area under the curve¼ 1.2e2) or cisplatin (25e30 mg/m2)] was
performed. If not, chemotherapy is delayed until bone marrow recovery. One cycle is
dose-dense chemotherapy continuing for 3 weeks followed by a 1-week break.
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means that tumors given less time to regrow between treatments
are more likely to be destroyed [2]. Despite the uncertain mecha-
nism, clinically, we have found therapeutic efﬁcacy of dose-denseFigure 2. The distribution of blood cell count [(A) neutrophils; (B) monocytes; (C) lympho
whisker plot. Absolute count of lymphocytes showed remarkable difference in the three s
dence interval; SE¼ standard error.chemotherapy in treating ovarian epithelial cancer including ﬁrst-
line or salvaged settings. Moreover, it is noteworthy that dose-
dense chemotherapy is effectively applied even for platinum-
resistant disease. Many researchers have reported that the pa-
tients receiving dose-dense chemotherapy have better tolerance
and a higher response rate (about 43e60%) [3,4].
Recently, many studies have investigated the mechanism of
dose-dense chemotherapy, either the cytotoxic or immunogenic
effect. Previously we have documented a correlation between the
induction of serum interferon-g and interleukin-2 and the efﬁcacy
of chemotherapy by weekly low-dose carboplatin and paclitaxel in
the patients having platinum-resistant ovarian cancer, indicating a
role of antitumor immunity in dose-dense chemotherapy [5].
Cancer patients who receive multiple chemotherapies are usu-
ally immunocompromised. They are relatively difﬁcult to be
induced strong antitumor immunity. Clinically there is a need to
evaluate which patient would beneﬁt from this mode of dose-
dense treatment. We conducted this study in order to determine
if therewere hematological markers [neutrophil count, lymphocyte
count, platelet count, monocyte count, and ratios, such as platelet/
neutrophil ratio (PNR), neutrophil/lymphocyte ratio (NLR), platelet/
lymphocyte ratio (PLR), neutrophil/monocyte ratio (NMR), platelet/
monocyte ratio (PMR), and lymphocyte/monocyte ratio (LMR)] in
patients with ovarian cancer receiving dose-dense chemotherapy.
Materials and methods
Patient selection
From 2009 to 2014 (Table 1), primary or recurrent epithelial
ovarian cancer patients who had received dose-dense chemo-
therapy as adjuvant or salvage chemotherapy in MacKay Memo-
rial Hospital, Taipei, Taiwan were enrolled in our retrospective
study.cytes; (D) platelets] in nonresponsive, stable, and responsive groups: using box-and-
ubgroups. 0¼ nonresponsive; 1¼ stable; 2¼ responsive; Mean ± 1.96 SE¼ 95% conﬁ-
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We started to retrieve the data after getting the approval of the
institutional review board. From the medical records we ﬁrst
excluded the patients of tumor marker CA125 noninformative
subgroup (pretreatment CA125 was < 35 U/mL). We documented
the hematologic data of everyweekly pretreatment complete blood
count and also calculated the six ratios by division of any two basic
blood cell counts: PLR, PNR, PMR, NLR, NMR, and LMR during the
dose-dense chemotherapy treatment period. Monthly tumor
marker CA125 was collected due to an index of the deﬁnition of
dose-dense chemotherapy efﬁcacy.
Schedule for dose-dense chemotherapy in MacKay Memorial
Hospital
The schedule for dose-dense chemotherapy in MacKay Memo-
rial Hospital (Figure 1) was paclitaxel (60e80mg/m2) and platinum
[carboplatin (area under the curve¼ 1.2e2) or cisplatin (25e30mg/
m2)] on Day 1, Day 8, and Day 15, every 28 days as one cycle. Our
patients received routine blood tests including complete blood
count and biochemistry proﬁle (fasting sugar, liver enzyme, renalFigure 3. The distribution of ratios [(A) platelet/lymphocyte ratio (PLR); (B) platelet/neutr
(NLR); (E) neutrophil/monocyte ratio (NMR); (F) lymphocyte/monocyte ratio (LMR)] in non
showed remarkable difference in the three subgroups. 0¼ nonresponsive; 1¼ stable; 2 ¼ rfunction, and electrolyte: Naþ, Kþ and Cle) on the morning of the
treatment day.
The eligibility criteria for blood tests were: adequate bone
marrow (absolute neutrophil count > 1500/mL, platelets > 100 K/
mL); liver enzyme (pretreatment alanine aminotransferase and/or
aspartate aminotransferase  2 upper limit of normal); and renal
function (creatinine  1.2 mg/dL). The exclusion criteria for blood
tests were thrombocytopenia (platelets < 100 109/L), or neu-
tropenia (absolute neutrophil count < 1500 106/L), or infection
episode [signs or symptoms: fever ( 38C), leukocytosis (white
blood cells  10 109/L), or positive result of blood or urine cul-
ture]. In these cases, chemotherapy should be delayed and restarted
after condition resolution.
The deﬁnition of dose-dense chemotherapy efﬁcacy
We deﬁned the efﬁcacy of dose-dense chemotherapy by
monthly CA125 levels [6,7]. We evaluated the trend of CA125 of
each patient and grouped the treatment course into three possible
different responses. There are three kinds of treatment response:
responsive, stable, and nonresponsive periods (some courses may
have only one kind of treatment response).ophil ratio (PNR); (C) platelet/monocyte ratio (PMR); (D) neutrophil/lymphocyte ratio
responsive, stable, and responsive groups: using box-and-whisker plot. PLR and NLR
esponsive; Mean ± 1.96 SE¼ 95% conﬁdence interval; SE¼ standard error.
Table 2
Statistical analysis (1-way ANOVA post hoc-Tukey honest signiﬁcant difference test)
for absolute count of lymphocytes, absolute count of platelets, platelet/lymphocyte
ratio (PLR), platelet/neutrophil ratio (PNR), platelet/monocyte ratio (PMR), neutro-
phil/lymphocyte ratio (NLR), comparison of nonresponsive versus stable, nonre-
sponsive versus responsive, stable versus responsive subgroups; marked differences
are signiﬁcant at p< 0.05.
Nonresponsive Stable Responsive
Absolute count of lymphocytes
Nonresponsive d < 0.001 < 0.001
Stable < 0.001 d 0.103
Responsive < 0.001 0.103 d
Absolute count of platelets
Nonresponsive d 0.719 < 0.001
Stable 0.714 d 0.002
Responsive < 0.001 0.002 d
PLR
Nonresponsive d 0.002 < 0.001
Stable 0.002 d 0.874
Responsive < 0.001 0.874 d
PNR
Nonresponsive d 0.682 < 0.001
Stable 0.682 d < 0.001
Responsive < 0.001 < 0.001 d
PMR
Nonresponsive d 0.831 < 0.001
Stable 0.831 d 0.042
Responsive < 0.001 0.042089 d
NLR
Nonresponsive d 0.037 0.017
Stable 0.037 d 0.652
Responsive 0.017 0.652 d
ANOVA¼ analysis of variance.
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pretreatment point to the nadir point of CA125  50%, or dropped
below the upper limit of normal (35 U/mL).
Stable period: ineligible periods of responsive or nonresponsive
criteria, or stationary CA125 levels but greater than upper limit of
normal (35 U/mL).
Nonresponsive period: the trend of CA125was elevated, doubling
of CA-125 levels from either the upper limit of normal (35 U/mL) or
the nadir CA-125 level.
Statistical analysis and comparison
We grouped 55 cases (totally 67 courses of dose-dense
chemotherapies) into three different treatment periods
(responsive, stable, and nonresponsive) according to CA125
trend. The three different periods of blood cell count or ratio
were analyzed using one-way analysis of variance and using
post hoc-Tukey test. A p value < 0.05 was considered to be
statistically signiﬁcant. Statistical analysis was performed using
STATISTICA software (Dell Software in Tulsa, Oklahoma, USA).
Results
From 2009 to 2014, there were 55 patients with ovarian cancer
who received dose-dense chemotherapy recruited into this study.
Some patients had two or three treatment courses intermittently,
therefore, the total of treatment courses was 67. The median age of
the patients was 54.8 years with a range of 33e81 years. The me-
dian treatment duration was 194.6 days (range, 45e1122 days). Of
the 67 courses, 30 (45%) were prescribed for platinum-resistant or
persistent diseases.
Initially, we found that absolute count of lymphocytes, abso-
lute count of platelets, PLR, PNR, PMR (all p< 0.001), and NLR
(p¼ 0.013) had statistically signiﬁcant differences. Using box-
and-whisker plot, we further determined the distribution of
blood cell count or ratio in nonresponsive, stable, and responsive
subgroups (Figures 2 and 3). If the three boxes showed
remarkable discrepancy, this was signiﬁcant not only statistically
but also clinically. We found absolute count of lymphocytes, PLR,
and NLR had most remarkable discrepancy. In post hoc-Tukey
test, we analyzed the relationship between each two subgroups
comparison (Table 2; nonresponsive vs. stable, nonresponsive
vs. responsive, stable vs. responsive). If we combinated the
responsive and stable subgroups as identical effective treatment
subgroup in opposition to nonresponsive subgroup, we also
found the results of subdivision of p values (statistically signiﬁ-
cant in absolute count of lymphocytes, PLR, and NLR) in post
hoc-Tukey test were same as the results of box-and whisker plot
distribution.
In the clinical situation, we regard stable and responsive
response as effective treatment and usually keep the chemotherapy
regimen constant. Depending on post hoc-Tukey test, absolute
count of lymphocytes, PLR, and NLR showed statistical signiﬁcance
in the nonresponsive versus stable and nonresponsive versus
responsive subgroups. However, subgroup analysis for primary,
platinum-sensitive, and platinum-resistant patients demonstrated
that PLR and NLR correlated most to the outcome of dose-dense
chemotherapy (p< 0.001, p¼ 0.006, and p¼ 0.011 in primary,
platinum-sensitive, and platinum-resistant groups for PLR;
p¼ 0.006, p¼ 0.5, and p¼ 0.044 in primary, platinum-sensitive,
and platinum-resistant groups for NLR).
We concluded that PLR and NLR are possible markers for dose-
dense chemotherapy in treating ovarian cancer. These hematologic
markers are more available markers than CA125 and immunogenic
markers. Thus we can usually obtain relevant information from theweekly pretreatment hematologic data and decide the timing to
switch to another salvage chemotherapy regimen.
Discussion
Ovarian cancer is known to be associated with inﬂammation [8].
There is often a complex hostetumor relationship with most tu-
mors having inﬂammatory cells and mediators present in their
microenvironment [2]. This results in the production of chemo-
kines, cytokines, and prostaglandins, which not only recruit in-
ﬂammatory cells such as neutrophils, mast cells, and macrophages,
but also stimulate angiogenesis and cell proliferation [8]. Many
studies have reported that this process of lymphopenia has prog-
nostic signiﬁcance and is associated with poor outcome in a variety
of tumors including renal, pancreatic, and ovarian cancers [9,10].
Previous studies have demonstrated the association of both NLR
and PLR with poor prognosis in various tumor types. Recent
research reported that PLR is a novel independent prognostic
marker in patients with ovarian cancer [11e13]. However, most
studies explored the correlation between pretreatment or preop-
erative blood cell count or ratio and prognosis. There is no study
that showed these potential biomarker ﬂuctuation and treatment
response relationships during chemotherapy period. This is the ﬁrst
study to prove that PLR and NLR have dynamic correlation with
treatment response. From the distribution of hematologic markers
in nonresponsive, stable, and responsive subgroups, we can see
that the patients with lower PLR or lower NLR had better treatment
response for dose-dense chemotherapy.
Previously, we have documented a correlation between the in-
duction of serum interferon-g and interleukin-2 and the efﬁcacy of
chemotherapy by weekly low-dose carboplatin and paclitaxel in
the patients having platinum-resistant ovarian cancer, indicating a
role of antitumor immunity in the dose-dense chemotherapy [5].
We believed there should be a mechanism (other than cytotoxicity)
responsible for the tumor killing, which has been jeopardized in
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have noted that dose-dense chemotherapy acts through an
inﬂammasome-related pathway where NK and also gd T cells were
triggered (data not shown). The results of the recent studies suggest
that there may be a key of induced tumor-speciﬁc immune
response. In this regard, great interest has been generated in
elucidating the role of cancer inﬂammationwith tumor burden and
prognosis. It is well known that inﬂammation is associated with
different stages of tumor and development including initiation,
promotion, malignant conversion, invasion, and metastasis [2].
The role of dose-dense chemotherapy for ovarian cancer is
getting more important. In this study, we have not only established
the relation of hematologic counts and chemotherapy response but
also provided a possible surrogate marker to determine whether
we should continue the dose-dense chemotherapy in patients
receiving this mode of treatment. Further research elucidating the
underlying mechanism of this relation is mandated.
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